Fangzhou named "Outstanding Strategic Health Ecosystem Partner" at CIIE 2025
At the 8th China International Import Expo in Shanghai, Novo Nordisk expanded its Health Ecosystem Alliance and recognized Fangzhou Inc. (HKEX: 06086) as an "Outstanding Strategic Health Ecosystem Partner." The acknowledgment highlights Fangzhou's progress in AI-driven chronic disease programs and its growing role in weight and diabetes management. For leaders, this signals where healthcare operations are heading: tighter partnerships, AI infrastructure at the core, and measurable outcomes at scale.
What happened
Novo Nordisk's Health Ecosystem Alliance, launched in 2023, is a collaboration platform built to develop joint solutions for chronic disease care. Fangzhou, now a core member, has been working with Novo Nordisk since July 2025 under a strategic partnership focused on digital models that serve patients, providers, and payers. The two companies are moving care models from "disease-focused treatment" to proactive, continuous health management.
Why this matters for management
Digital health is moving from pilots to platforms. The Fangzhou-Novo Nordisk collaboration shows how pharma, AI, and providers can operate under shared goals to improve adherence, outcomes, and cost control. This is a playbook you can adapt across regions and conditions.
- Build partner ecosystems with shared KPIs: patient retention, adherence uplift, time-in-range, cost per controlled patient, and readmission rates.
- Make AI an operating layer, not a side project. Fangzhou is standardizing on its XJ and XS large language models to support end-to-end services.
- Shift from episodic care to continuous programs: remote monitoring, timely interventions, medication optimization, and outcome-based contracts.
- Standardize clinical pathways. Fangzhou's role in China's "AI + Weight Management" initiative shows how evidence and protocol design accelerate adoption.
- Design for scale: multi-condition expansion (weight, diabetes first), multilingual support, and modular integrations with EHRs and devices.
- Governance first: clinical validation, bias audits, consent flows, and data minimization that meet local regulations.
Fangzhou's execution so far
Fangzhou introduced the industry's first intelligent "AI + Weight Management" solution and was selected for the national "Healthy China: AI + Weight Management Initiative," working with the China Food and Drug Institutions Quality and Safety Promotion Association. In diabetes, Fangzhou's AI-enabled services and medication management won strong recognition from Novo Nordisk. By combining Fangzhou's digital infrastructure with Novo Nordisk's therapies for diabetes and obesity, they're building a connected ecosystem that supports patients across the full care cycle.
Dr. Xie Fangmin, Founder, Chairman, and CEO of Fangzhou, said the company will continue to lean on its XJ and XS large language models to deliver accessible, efficient, end-to-end chronic disease management for a wider population. The company's direction lines up with national goals under Healthy China 2030, with a focus on standardized, evidence-based models and open collaboration.
What to watch next
- Interoperability: seamless data exchange with hospitals, device makers, and pharmacies; real-time feedback loops for clinicians.
- Clinical evidence: peer-reviewed outcomes from AI-assisted programs, especially in adherence and metabolic improvements.
- Reimbursement models: expansion of bundled payments and outcomes-linked agreements to fund prevention and long-term management.
- Data protection: clear practices aligned with local regulations, patient consent, and auditability of AI decisions.
- Scalability: extending from weight and diabetes to other chronic conditions with reusable AI pipelines and care pathways.
For operators and P&L owners
- Define a chronic-care KPI stack now; measure leading indicators (engagement, early intervention rates) as well as clinical outcomes.
- Stand up an AI governance board that includes clinical, legal, data, and product leaders.
- Co-build with pharma and device partners; co-fund pilots tied to outcomes and unit economics, not feature lists.
- Invest in patient onboarding and clinician workflow fit-adoption lives or dies there.
About the companies
Novo Nordisk is a global healthcare company founded in 1923 and headquartered in Denmark. Its purpose is to drive change to defeat serious chronic diseases, with deep heritage in diabetes and expanding access to therapies. Learn more at novonordisk.com.
Fangzhou Inc. (HKEX: 06086) operates China's leading online chronic disease management platform, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025. The company delivers AI-enabled precision care and medication management across weight and diabetes, and continues to expand its digital ecosystem.
Level up your team's AI capability
If you're building or buying AI for healthcare operations, upskilling your managers shortens the learning curve. Explore role-based programs here: AI courses by job.
Your membership also unlocks:
